Physician profile
Suresh Kumar
NPI 1639375793
$7,045.48
in general payments reported to CMS, 2019-2025
29 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $480 · 2021: $1,510 · 2022: $1,345 · 2023: $1,012 · 2024: $1,044 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,901.77 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $887.28 | 2020-2021 | |
| Amgen INC. | $715.54 | 2019-2023 | Aimovig |
| Biohaven Pharmaceutical Holding Company Ltd. | $694.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $447.61 | 2019-2024 | Austedo Xr |
| Lundbeck LLC | $425.46 | 2020-2025 | Vyepti |
| Abbvie INC. | $372.25 | 2021-2025 | |
| Lilly USA, LLC | $257.78 | 2019-2025 | Kisunla, Amyvid |
| Harmony Biosciences LLC | $205.99 | 2022-2025 | Wakix |
| Mdd US Operations, LLC | $126.11 | 2019-2023 | Xadago, Apokyn |
| Neurelis, INC. | $125.82 | 2020-2023 | Valtoco |
| Allergan, INC. | $120.37 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $114.17 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $107.67 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $91.15 | 2025 | Symbravo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $77.18 | 2021-2024 | |
| Atland Pharmaceuticals, LLC | $46.90 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Upsher-Smith Laboratories LLC | $45.74 | 2020-2022 | |
| Genzyme Corporation | $36.95 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $30.71 | 2019 | |
| Biogen, INC. | $29.59 | 2021 | |
| Kyowa Kirin, INC. | $28.59 | 2020 | |
| Ucb, INC. | $26.28 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $25.03 | 2024 | Dysport |
| Scilex Pharmaceuticals INC. | $24.53 | 2024 | |
| Amneal Pharmaceuticals LLC | $24.04 | 2025 | Crexont |
| Impel Pharmaceuticals INC. | $22.71 | 2023 | Trudhesa |
| Metacel Pharmaceuticals LLC | $17.51 | 2022 | |
| Glaxosmithkline, LLC. | $16.66 | 2023 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.